Richard Neubig M.D., Ph.D.
Pharmacology & Toxicology, Michigan State University
Chair & Professor
B423 Life Sciences
1355 Bogue Street
East Lansing, MI 48824
Fields of Interest:
G protein-coupled receptor (GPCR) signaling and intracellular modulators of that signaling. GPCRs are the targets of over 25% of current drugs and we are discovering novel ways to control their function.
- Educational Background
- Biography & Current Research
- Awards & Achievements
- Committees & Activities:
B.S. (Chem), University of Michigan with highest honors
M.D., Harvard-MIT Program in Health Sciences and Technology
Harvard Medical School Ph.D., Pharmacology, Harvard
Resident Internal Medicine, University of Michigan Hospitals
Assistant Professor – Professor, Pharmacology, University of Michigan
Co-director, Center for Chemical Genomics, University of Michigan
Professor & Chair, Pharmacology & Toxicology, Michigan State University
- Research Synopsis: The central focus of work in the Neubig lab is on G protein-coupled receptor (GPCR) signaling and intracellular modulators of that signaling. GPCRs are the targets of over 25% of current drugs and we are discovering novel ways to control their function. There are three major programs in the lab.
- Standard techniques of drug discovery (high throughput screening, whole genome RNA interference, structure-based drug design, and animal models) have identified chemical modulators of RGS proteins (regulators of G protein signaling) with potential in neuropsychiatric disorders such as depression, pain, epilepsy, and Parkinson’s disease. We are current examining compound mechanisms and optimizing them for in vivo use.
- Gene transcriptional signaling downstream of the GTPase RhoA/C plays key roles in cancer metastasis and in diseases of fibrosis (scleroderma, pulmonary fibrosis, Crohn’s). Using HTS, we have identified two series of inhibitors of Rho/MRTF/SRF-regulated gene transcription. These compounds have shown efficacy in models of skin fibrosis and melanoma metastasis. Surprisingly, ras-mutant melanomas are particularly affected by our compounds.
- The role of G protein signaling and its control by RGS proteins in brain is explored with mutant mouse models. One model exhibits seizures and sudden death. The mechanism of this is being explored relevant to human epilepsy syndromes such as epileptogenic encephalopathy and Fragile X syndrome.
- Phi Beta Kappa, University of Michigan, 1974
- American Institute of Chemists Award, 1975
- Medical Scientist Trainee Program Fellowship, NIH, 1976-1981
- Hartford Foundation Fellowship, 1983-1986
- American Heart Association Established Investigator, 1987-1993
- ASPET-Astellas Award in Translational Pharmacology, 2009
- Pharmacia-ASPET Award for Experimental Therapeutics, 2013
- Invited speaker, Nobel Forum on GPCRs, Stockholm, June 2003
- NIH Pharmacology (PHRA) Study Section, 1996-2000 (Chair, 1999-2000)
- NIH Molecular and Integrative Signal Transduction (MIST) Study Section, 2007-2010 (Chair),
- Journal of Biological Chemistry, 1992-1997
- Molecular Pharmacology, 1992-
- Associate Editor 1996-1999
- Molecular InTERventions, 2000-2012
- Chemical Biology & Drug Discovery, 2006-
- NC-IUPHAR Receptor Nomenclature (2001-)
National & International Society Committees:
- President, ASPET, 2012-2015
- Chair, Molecular Pharmacology Division, ASPET, 1997-2002 (Founding chair, 1997 - 1999)
- IUPHAR Receptor Nomenclature Committee, Vice-Chair for GPCRs
- NIH Director’s New Innovator Awards Panel, 2010
- NCATS X02 Therapeutics Discovery Review, 2012.
- Redox modification of nuclear actin by MICAL-2 regulates SRF signaling. Mark R. Lundquist, Andrew J. Storaska, Ting-Chun Liu, Scott D. Larsen, Todd Evans, Richard R. Neubig, and Samie R. Jaffrey. Cell, 2014 in press.
- Optimization of novel nipecotic bis(amide) inhibitors of the Rho/MKL1/SRF transcriptional pathway as potential anti-metastasis agents. Bell JL, Haak AJ, Wade SM, Kirchhoff PD, Neubig RR, Larsen SD. Bioorg Med Chem Lett. 2013 Jul 1;23(13):3826-32. doi: 10.1016/j.bmcl.2013.04.080. Epub 2013 May 7. PMID: 23707258
- Conformational dynamics of a regulator of G-protein signaling protein reveals a mechanism of allosteric inhibition by a small molecule. Vashisth H, Storaska AJ, Neubig RR, Brooks CL 3rd. ACS Chem Biol. 2013 Dec 20;8(12):2778-84. doi: 10.1021/cb400568g. Epub 2013 Oct 24. PMID: 24093330
- Cardiotonic steroids stabilize regulator of G protein signaling 2 protein levels. Sjögren B, Parra S, Heath LJ, Atkins KB, Xie ZJ, Neubig RR. Mol Pharmacol. 2012 Sep;82(3):500-9. doi: 10.1124/mol.112.079293. Epub 2012 Jun 13. PMID: 22695717
- RGS inhibition at G(alpha)i2 selectively potentiates 5-HT1A-mediated antidepressant effects. Talbot JN, Jutkiewicz EM, Graves SM, Clemans CF, Nicol MR, Mortensen RM, Huang X, Neubig RR, Traynor JR. Proc Natl Acad Sci U S A. 2010 Jun 15;107(24):11086-91. doi: 10.1073/pnas.1000003107. Epub 2010 Jun 2. PMID:20534514
Additional articles at PubMed